Biotechnology

On the Eve of BIO 2026, Chinese Innovative Assets Trigger a New Wave of Global Collaborations

SAN DIEGO , July 8, 2026 /PRNewswire/ -- On the eve of the highly anticipated BIO International Convention 2026, theBIOSeedin Summer Innovation Partnering Summit successfully took place in San Diego. Hosted by bioSeedin and proudly supported by strategic partners Thermo Fisher Scientific and ACRO...

2026-07-09 00:00 920

Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026

MONTPELLIER, France, July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading conferences dedicated to therapeutic antibodies and biotherapeutics. At the event, the company...

2026-07-08 22:17 1097

WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year

* Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) * Included in the MSCI ESG Selection Indexes for the fourth consecutive year * Leader in Green CRDMO solutions for a healthier future SHANGHAI, July 8, 2026 /PRNewswire/ -- WuXi Bi...

2026-07-08 15:15 2245

OTR Therapeutics Enters Strategic Collaboration with LG Chem to Accelerate Development of Novel Oncology Therapies

SHANGHAI, July 7, 2026 /PRNewswire/ -- OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, today announced that it has entered into a strategic collaboration agreement with LG Chem, a leading global company ...

2026-07-08 07:00 1939

Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

* Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature Medicine * Rentosertib represents a novel mec...

2026-07-07 21:43 2860

Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones

MUMBAI, India, July 7, 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capab...

2026-07-07 20:50 2843

Strategic Collaboration | Sanyou Bio and Baiyunshan Xihe Join Forces to Advance Innovative Radiopharmaceuticals and Radiodiagnostics

SHANGHAI and GUANGZHOU, China, July 4, 2026 /PRNewswire/ -- Sanyou Biopharmaceutical Co., Ltd. ("Sanyou Bio") and Guangzhou Baiyunshan Xihe Health Pharmaceutical Co., Ltd. ("Baiyunshan Xihe") jointly announced the official signing of a strategic cooperation agreement. This partnership will focus ...

2026-07-04 23:25 5621

Sky Labs Showcases 'CART BP pro' for Potential Use in Drug Clinical Trials on Global Stage

BASEL, Switzerland and SEOUL, South Korea, July 3, 2026 /PRNewswire/ -- Sky Labs (CEO Jack Byunghwan Lee) announced on the 2nd that it introduced its data platform business at the 9th Digital Biomarkers in Clinical Trials Summit in Basel, Switzerland, highlighting the potential of its ring-type c...

2026-07-03 16:14 3904

Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence

CAMBRIDGE, Mass., July 2, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Peng Wang as Chief Operating Officer (COO). Dr. Wang will be...

2026-07-03 09:36 3036

SK bioscience Launches AI-Powered Initiative to Reduce Uncertainty in Vaccine-Development Decisions

* SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework. * SK bioscience, PATH, Slalom, and SK AX will jointly develop an AI-powered platform for evidence-based clinical development decision-making. * The project will supp...

2026-07-02 20:00 2858

Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration a...

2026-07-02 10:16 2861

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel I...

2026-07-02 09:00 2703

Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases

CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced a strategic collaboration with Lonza to develop best-in-class single-domain antibody–base...

2026-07-02 08:05 2435

PharmaResearch Accelerates REJURAN Cosmetics Expansion Across North and South America with Planned Acquisition of CG USA

Acquisition strengthens local manufacturing and logistics capabilities as REJURAN Cosmetics expands across Sephora, Amazon and Canada, with future growth across the Americas in view  SEOUL, South Korea, July 1, 2026 /PRNewswire/ -- PharmaResearch, the South Korea-based regenerative medicine comp...

2026-07-01 13:38 4041

ALR Technologies Announces Strategic Acquisition of CGM Medical Technology for US$45 Million & 200M Shares

SINGAPORE, June 30, 2026 /PRNewswire/ -- ALR Technologies SG Ltd ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces it has entered into a Letter of Intent ("LOI") to acquire 100% equity of CGM Medical Technology Singapore Pte. Ltd. ("CGM Medical Singapore") and ass...

2026-06-30 23:26 8159

Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics

SHANGHAI, June 30, 2026 /PRNewswire/ -- Tsingke Biotech recently hosted the Oligonucleotide Drug Salon at the Hilton Shanghai Zhangjiang, bringing together experts from academia, biopharmaceutical companies, investment firms, and industry service organizations to discuss technological innovation,...

2026-06-30 22:17 2843

Bota Biosciences and BASF Introduce Bio-Identical Collagen III Powered by AI

PULNOY, France and HANGZHOU, China, June 30, 2026 /PRNewswire/ -- Bota Biosciences and BASF jointly announced the market launch of BASF's SkinNexus™ Collag3n. This 100% human-identical recombinant Collagen III fragment was developed in collaboration between the two companies and is being commerc...

2026-06-30 21:00 1948

Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth

* Advanced environmental performance through renewable energy transition and enhanced carbon transparency * Strengthened sustainability management and supply chain engagement across the healthcare value chain INCHEON, South Korea, June 30, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.K...

2026-06-30 19:00 2290

WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy

WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together ...

2026-06-30 13:49 1249

EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026

SAN DIEGO, June 30, 2026 /PRNewswire/ -- At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) service platform. The company actively pursued U.S. market...

2026-06-30 13:36 1866
12345 ... 167